All In Biotech

Free tool

FAERS Monitor: Technescan Mag3

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019882 or its brand name (Technescan Mag3, Technetium Tc-99m Mertiatide Kit). Reports on generic versions are filed under their own applications.

Reports

103

Serious

42

41% of reports

Hospitalization

12

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective16
  • dyspnoea11
  • radioisotope scan abnormal9
  • renal scan abnormal8
  • syncope8
  • tachycardia7
  • drug dispensing error6
  • nausea6
  • rash6
  • vomiting6
  • urticaria5
  • wrong drug administered5
  • dizziness4
  • headache4
  • hyperhidrosis4

Reports by year received

View as table
YearReports
20043
20051
20071
20084
20094
201010
20112
20121
20134
20151
20161
20177
201810
201919
202022
20218
20221
20253
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,056 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
renal scan abnormalSignal825956.612763.4161,930
radioisotope scan abnormalSignal92635.61405.820,873
wrong drug administeredSignal5114.648.7455
drug dispensing errorSignal680.236.9394
syncopeSignal816.38.4101
tachycardiaSignal716.17.985
hyperhidrosisSignal46.32.413
urticariaSignal56.12.617
dyspnoeaSignal114.02.322
rashSignal62.81.35
vomitingSignal62.61.25
drug ineffectiveSignal162.51.614
dizziness41.60.60
nausea61.50.71
headache41.30.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.